Final CHAMPION MG Trial Data Show Sustained Benefit, Safety of Ravulizumab in Myasthenia Gravis

Published Date: 24 Apr 2025

Results from the open-label extension of a phase 3 trial showed that treatment with ravulizumab sustained clinical benefits for up to 4 years in patients with generalized myasthenia gravis.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Potential targets for treating the most common type of liver cancer in children have been identified by a collaborative study.

2.

Study identifies new approach to protect the brain during radiation therapy

3.

While most cancer screenings won't prolong lives, there are still good reasons to continue screening.

4.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

5.

Radiation therapy for patients with breast cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot